(Q35772029)

10 August 2017

1 reference

title

Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes (English)

1 reference

10 August 2017

David A D'Alessio

1

1 reference

10 August 2017

Torsten P Vahl

series ordinal

2

1 reference

10 August 2017

publication date

1 June 2004

1 reference

American Journal of Physiology - Endocrinology and Metabolism

10 August 2017

published in

1 reference

10 August 2017

volume

286

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

E882-90

1 reference

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide 1 elevates cytosolic calcium in pancreatic beta-cells independently of protein kinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Interaction with grp58 increases activity of the thiazide-sensitive Na-Cl cotransporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide-1: a potent regulator of food intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Functional maturation of fetal porcine beta-cells by glucagon-like peptide 1 and cholecystokinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

The enteroinsular axis in dipeptidyl peptidase IV-negative rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Elevated glucagon-like peptide-1-(7-36)-amide, but not glucose, associated with hyperinsulinemic compensation for fat feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucagon-like peptide-1 is a physiological incretin in rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

GLP-1 does not acutely affect insulin sensitivity in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00014.2004

10.1152/AJPENDO.00014.2004

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference